Tandem settles patent disputes with Roche, agrees to pay $36M over five years

TANDEM DIABETES CARE INC

Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.
Total consideration $36M; initial $8M payment due, remainder in four equal annual installments.
Parties exchange non-exclusive, non-royalty-bearing cross-licenses to insulin delivery system patents for 10 years.
Tandem and Roche mutually release claims and covenant not to sue related to the disputed patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.